In this study, XIAP siRNA was used to establish an in vivo mouse model to determine whether XIAP acts as a negative regulator in HFD-induced NAFLD through the suppression of oxidative stress. Here, XIAP is linked to metabolic dysfunction-associated steatotic liver disease.